Advanced search
Start date
Betweenand
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Decreased glycolytic metabolism in non-compaction cardiomyopathy by F-18-fluoro-2-deoxyglucose positron emission tomography: new insights into pathophysiological mechanisms and clinical implications

Full text
Author(s):
Show less -
Tavares de Melo, Marcelo Dantas ; Pinto Giorgi, Maria Clementina ; Assuncao, Jr., Antonildes Nascimento ; Dantas, Jr., Roberto Nery ; Araujo Filho, Jose de Arimateia ; Parga Filho, Jose Rodrigues ; de Souza Bierrenbach, Ana Luiza ; de Lima, Camila Rocon ; Soares, Jr., Jose ; Meneguetti, Jose Claudio ; Mady, Charles ; Hajjar, Ludhmila Abrahao ; Kalil Filho, Roberto ; Bocchi, Edimar Alcides ; Cury Salemi, Vera Maria
Total Authors: 15
Document type: Journal article
Source: EUROPEAN HEART JOURNAL-CARDIOVASCULAR IMAGING; v. 18, n. 8, p. 915-921, AUG 2017.
Web of Science Citations: 1
Abstract

Aims The pathophysiological mechanisms of left ventricular non-compaction cardiomyopathy (LVNC) remain controversial. This study performed combined F-18-fluoro-2-deoxyglucose dynamic positron emission tomography (FDG-PET) and 99mTc-sestamibi single-photon emission computed tomography (SPECT) studies to evaluate myocardial glucose metabolism and perfusion in patients with LVNC and their clinical implications. Methods and results Thirty patients (41 +/- 12 years, 53% male) with LVNC, diagnosed by cardiovascular magnetic resonance (CMR) criteria, and eight age-matched healthy controls (42 +/- 12 years, 50% male) were prospectively recruited to undergo FDG-PET with measurement of the myocardial glucose uptake rate (MGU) and SPECT to investigate perfusion-metabolism patterns. Patients with LVNC had lower global MGU compared with that in controls (36.9 +/- 8.8 vs. 44.6 +/- 5.4 mu mol/min/100 g, respectively, P = 0.02). Of 17 LV segments, MGU levels were significantly reduced in 8, and also a reduction was observed when compacted segments from LVNC were compared with the segments from control subjects (P < 0.001). Perfusion defects were also found in 15 (50%) patients (45 LV segments: 64.4% match, and 35.6% mismatch perfusion-metabolism pattern). Univariate and multivariate analyses showed that beta-blocker therapy was associated with increased MGU (beta coefficient = 10.1, P = 0.008). Moreover, a gradual increase occurred in MGU across the beta-blocker dose groups (P for trend = 0.01). Conclusion The reduction of MGU documented by FDG-PET in LVNC supports the hypothesis that a cellular metabolic pathway may play a role in the pathophysiology of LVNC. The beneficial effect of beta-blocker mediating myocardial. (AU)

FAPESP's process: 10/18939-3 - Microcirculatory and glycolytic metabolism evaluation in isolated noncompaction cardiomyopathy
Grantee:Vera Maria Cury Salemi
Support type: Regular Research Grants